Why daratumumab is effective in multiple myeloma - results from the CASTOR trial
The success story of indolent disease treatment expanded to difficult-to-treat patient groups
Venetoclax combination therapy for relapsed CLL
The IFM 2012-03 trial: what will the next step be?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?